Cardiol Therapeutics Inc. Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David G. Elsley
- Full Time Employees
- 23
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 2265 Upper Middle Road East Oakville ON Canada L6H 0G5
- IPO Date
- Dec 20, 2018
- Website
- cardiolrx.com
- Similar Companies
- Business
- Cardiol Therapeutics Inc. is a clinical-stage biopharmaceutical firm dedicated to the research and development of anti-inflammatory and anti-fibrotic treatments for heart conditions. Their primary therapeutic candidate, CardiolRx™, an oral cannabidiol formulation, is progressing through clinical trials. It is currently in a Phase III multi-national, randomized, double-blind, placebo-controlled study (MAVERIC) to evaluate its effectiveness in preventing recurrent pericarditis, a debilitating inflammatory heart disease. Additionally, CardiolRx™ is undergoing a Phase II multi-national, randomized, double-blind, placebo-controlled trial (ARCHER) to assess its impact on myocardial recovery in patients with acute myocarditis, a serious condition affecting the heart muscle. The company is also developing CRD-38, a novel subcutaneously administered cannabidiol formulation, which is in preclinical stages for the treatment of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Company News
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Contrasting Corcept Therapeutics (NASDAQ:CORT) & Cardiol Therapeutics (NASDAQ:CRDL)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Cardiol Therapeutics Announces Year-End 2025 Update on Operations